Wonderivy的个人主页 - 老虎社区

Wonderivy

Wonderivy

暂无个人介绍

IP属地：未知

9关注

1粉丝

0主题

0勋章

2021-12-10

Good

Some vaccine stocks dropped in premarket trading<blockquote>部分疫苗股盘前交易下跌</blockquote>

2021-12-10

Ok

Broadcom stock jumped nearly 7% in premarket trading<blockquote>博通股价在盘前交易中上涨近 7%</blockquote>

2021-11-20

Ok

Pfizer and BioNTech SE stocks climbed about 2% in premarket trading<blockquote>辉瑞和 BioNTech SE 股票在盘前交易中上涨约 2%</blockquote>

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4095056182380350","uuid":"4095056182380350","gmtCreate":1631953243625,"gmtModify":1639061790382,"name":"Wonderivy","pinyin":"wonderivy","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/6baa7ecbc66f9246e804ad8342fd6e05","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":9,"tweetSize":3,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-3","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"偶像虎友","description":"加入老虎社区1500天","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.04.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":605847523,"gmtCreate":1639148356892,"gmtModify":1639148356892,"author":{"id":"4095056182380350","authorId":"4095056182380350","name":"Wonderivy","avatar":"https://static.tigerbbs.com/6baa7ecbc66f9246e804ad8342fd6e05","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4095056182380350","idStr":"4095056182380350"},"themes":[],"title":"","htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/605847523","repostId":"1100115506","repostType":4,"repost":{"id":"1100115506","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639138188,"share":"https://www.laohunote.com/m/news/1100115506?lang=zh_CN&edition=full","pubTime":"2021-12-10 20:09","market":"us","language":"en","title":"Some vaccine stocks dropped in premarket trading<blockquote>部分疫苗股盘前交易下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1100115506","media":"Tiger Newspress","summary":"Some vaccine stocks dropped in premarket trading.Moderna fell more than 6%,BioNTech and Novavax fell","content":"<p>Some vaccine stocks dropped in premarket trading.Moderna fell more than 6%,BioNTech and Novavax fell about 2%.</p><p><blockquote>一些疫苗股在盘前交易中下跌。Moderna下跌超过6%，BioNTech和Novavax下跌约2%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/8a520d484bb38c42dea515aeca96c8b3\" tg-width=\"843\" tg-height=\"623\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/3f4e9ce656bcb771198057d217489677\" tg-width=\"843\" tg-height=\"618\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/fd626ba47bec50af63916a31695eca4c\" tg-width=\"843\" tg-height=\"621\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Some vaccine stocks dropped in premarket trading<blockquote>部分疫苗股盘前交易下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSome vaccine stocks dropped in premarket trading<blockquote>部分疫苗股盘前交易下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-10 20:09</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Some vaccine stocks dropped in premarket trading.Moderna fell more than 6%,BioNTech and Novavax fell about 2%.</p><p><blockquote>一些疫苗股在盘前交易中下跌。Moderna下跌超过6%，BioNTech和Novavax下跌约2%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/8a520d484bb38c42dea515aeca96c8b3\" tg-width=\"843\" tg-height=\"623\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/3f4e9ce656bcb771198057d217489677\" tg-width=\"843\" tg-height=\"618\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/fd626ba47bec50af63916a31695eca4c\" tg-width=\"843\" tg-height=\"621\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","MRNA":"Moderna, Inc.","BNTX":"BioNTech SE"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1100115506","content_text":"Some vaccine stocks dropped in premarket trading.Moderna fell more than 6%,BioNTech and Novavax fell about 2%.","news_type":1,"symbols_score_info":{"NVAX":0.9,"BNTX":0.9,"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":3730,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605844711,"gmtCreate":1639148305207,"gmtModify":1639148305207,"author":{"id":"4095056182380350","authorId":"4095056182380350","name":"Wonderivy","avatar":"https://static.tigerbbs.com/6baa7ecbc66f9246e804ad8342fd6e05","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4095056182380350","idStr":"4095056182380350"},"themes":[],"title":"","htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/605844711","repostId":"1191100998","repostType":4,"repost":{"id":"1191100998","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639134697,"share":"https://www.laohunote.com/m/news/1191100998?lang=zh_CN&edition=full","pubTime":"2021-12-10 19:11","market":"us","language":"en","title":"Broadcom stock jumped nearly 7% in premarket trading<blockquote>博通股价在盘前交易中上涨近 7%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1191100998","media":"Tiger Newspress","summary":"Broadcom stock jumped nearly 7% in premarket trading as the semiconductor firm saw upbeat first-quar","content":"<p>Broadcom stock jumped nearly 7% in premarket trading&nbsp;as&nbsp;the&nbsp;semiconductor firm saw upbeat first-quarter sales, unveiled $10 bln buyback plan.</p><p><blockquote>博通股价在盘前交易中上涨近 7%，这家半导体公司第一季度销售乐观，并公布了 100 亿美元的回购计划。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/f168e8acd44244ccac5c7ae151b9c6be\" tg-width=\"840\" tg-height=\"617\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> Semiconductor firm Broadcom Inc&nbsp;forecast first-quarter revenue above Wall Street expectations and announced a $10 billion share buyback plan on Thursday, banking on a rebound in enterprise spending and sustained demand from cloud computing companies.</p><p><blockquote>半导体公司博通公司预测第一季度收入高于华尔街预期，并于周四宣布了一项 100 亿美元的股票回购计划，指望企业支出反弹和云计算公司的持续需求。</blockquote></p><p> Analysts have pointed to strong near-term demand for Broadcom's radio frequency and wireless chips as telecom firms spend more to roll out 5G technology, and continued strength in its broadband division. The company counts smartphone giants Apple Inc&nbsp;and Samsung Electronics&nbsp;among major customers.</p><p><blockquote>分析师指出，随着电信公司投入更多资金推出 5G 技术，以及其宽带部门持续走强，近期对博通射频和无线芯片的需求强劲。该公司的主要客户包括智能手机巨头苹果公司和三星电子。</blockquote></p><p> Broadcom is also poised to benefit from higher demand for its data-center and server chips, aided by a rise in hybrid working models and a rapid shift to cloud by businesses during the pandemic.</p><p><blockquote>得益于混合工作模式的兴起以及大流行期间企业向云的快速转变，博通还将受益于对其数据中心和服务器芯片的更高需求。</blockquote></p><p> Enterprise demand rebounded sharply over 30% in the reported quarter, while revenue from semiconductor solutions is expected to grow 17% in the current quarter, Chief Executive Hock Tan said on a conference call with analysts.</p><p><blockquote>首席执行官 Hock Tan 在与分析师举行的电话会议上表示，报告季度企业需求大幅反弹超过 30%，而本季度半导体解决方案收入预计将增长 17%。</blockquote></p><p> The San Jose, California-based company forecast first-quarter revenue of about $7.60 billion, well above analysts' average estimate of $7.25 billion, according to Refinitiv data.</p><p><blockquote>根据 Refinitiv 的数据，这家总部位于加利福尼亚州圣何塞的公司预计第一季度收入约为 76.0 亿美元，远高于分析师平均预期的 72.5 亿美元。</blockquote></p><p> Fourth-quarter revenue rose 15% to $7.41 billion, narrowly beating estimates of $7.36 billion, while earnings per share of $7.81 was also better than expected.</p><p><blockquote>第四季度收入增长 15%，达到 74.1 亿美元，略高于预期的 73.6 亿美元，而每股收益 7.81 美元也好于预期。</blockquote></p><p> Broadcom has also diversified beyond its core chip business and forayed into the lucrative software arena, at a time when the world grapples with supply chain disruptions and an industry-wide chip shortage. Its infrastructure software revenue grew 8% to $1.77 billion in the fourth quarter.</p><p><blockquote>在全球努力应对供应链中断和全行业芯片短缺之际，博通还在核心芯片业务之外实现了多元化，进军利润丰厚的软件领域。第四季度其基础设施软件收入增长 8%，达到 17.7 亿美元。</blockquote></p><p> The new share repurchase program is effective until the end of next year, the company said in a separate statement.</p><p><blockquote>该公司在另一份声明中表示，新的股票回购计划有效期至明年年底。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Broadcom stock jumped nearly 7% in premarket trading<blockquote>博通股价在盘前交易中上涨近 7%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBroadcom stock jumped nearly 7% in premarket trading<blockquote>博通股价在盘前交易中上涨近 7%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-10 19:11</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Broadcom stock jumped nearly 7% in premarket trading&nbsp;as&nbsp;the&nbsp;semiconductor firm saw upbeat first-quarter sales, unveiled $10 bln buyback plan.</p><p><blockquote>博通股价在盘前交易中上涨近 7%，这家半导体公司第一季度销售乐观，并公布了 100 亿美元的回购计划。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/f168e8acd44244ccac5c7ae151b9c6be\" tg-width=\"840\" tg-height=\"617\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> Semiconductor firm Broadcom Inc&nbsp;forecast first-quarter revenue above Wall Street expectations and announced a $10 billion share buyback plan on Thursday, banking on a rebound in enterprise spending and sustained demand from cloud computing companies.</p><p><blockquote>半导体公司博通公司预测第一季度收入高于华尔街预期，并于周四宣布了一项 100 亿美元的股票回购计划，指望企业支出反弹和云计算公司的持续需求。</blockquote></p><p> Analysts have pointed to strong near-term demand for Broadcom's radio frequency and wireless chips as telecom firms spend more to roll out 5G technology, and continued strength in its broadband division. The company counts smartphone giants Apple Inc&nbsp;and Samsung Electronics&nbsp;among major customers.</p><p><blockquote>分析师指出，随着电信公司投入更多资金推出 5G 技术，以及其宽带部门持续走强，近期对博通射频和无线芯片的需求强劲。该公司的主要客户包括智能手机巨头苹果公司和三星电子。</blockquote></p><p> Broadcom is also poised to benefit from higher demand for its data-center and server chips, aided by a rise in hybrid working models and a rapid shift to cloud by businesses during the pandemic.</p><p><blockquote>得益于混合工作模式的兴起以及大流行期间企业向云的快速转变，博通还将受益于对其数据中心和服务器芯片的更高需求。</blockquote></p><p> Enterprise demand rebounded sharply over 30% in the reported quarter, while revenue from semiconductor solutions is expected to grow 17% in the current quarter, Chief Executive Hock Tan said on a conference call with analysts.</p><p><blockquote>首席执行官 Hock Tan 在与分析师举行的电话会议上表示，报告季度企业需求大幅反弹超过 30%，而本季度半导体解决方案收入预计将增长 17%。</blockquote></p><p> The San Jose, California-based company forecast first-quarter revenue of about $7.60 billion, well above analysts' average estimate of $7.25 billion, according to Refinitiv data.</p><p><blockquote>根据 Refinitiv 的数据，这家总部位于加利福尼亚州圣何塞的公司预计第一季度收入约为 76.0 亿美元，远高于分析师平均预期的 72.5 亿美元。</blockquote></p><p> Fourth-quarter revenue rose 15% to $7.41 billion, narrowly beating estimates of $7.36 billion, while earnings per share of $7.81 was also better than expected.</p><p><blockquote>第四季度收入增长 15%，达到 74.1 亿美元，略高于预期的 73.6 亿美元，而每股收益 7.81 美元也好于预期。</blockquote></p><p> Broadcom has also diversified beyond its core chip business and forayed into the lucrative software arena, at a time when the world grapples with supply chain disruptions and an industry-wide chip shortage. Its infrastructure software revenue grew 8% to $1.77 billion in the fourth quarter.</p><p><blockquote>在全球努力应对供应链中断和全行业芯片短缺之际，博通还在核心芯片业务之外实现了多元化，进军利润丰厚的软件领域。第四季度其基础设施软件收入增长 8%，达到 17.7 亿美元。</blockquote></p><p> The new share repurchase program is effective until the end of next year, the company said in a separate statement.</p><p><blockquote>该公司在另一份声明中表示，新的股票回购计划有效期至明年年底。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AVGO":"博通"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191100998","content_text":"Broadcom stock jumped nearly 7% in premarket trading as the semiconductor firm saw upbeat first-quarter sales, unveiled $10 bln buyback plan.\n\nSemiconductor firm Broadcom Inc forecast first-quarter revenue above Wall Street expectations and announced a $10 billion share buyback plan on Thursday, banking on a rebound in enterprise spending and sustained demand from cloud computing companies.\nAnalysts have pointed to strong near-term demand for Broadcom's radio frequency and wireless chips as telecom firms spend more to roll out 5G technology, and continued strength in its broadband division. The company counts smartphone giants Apple Inc and Samsung Electronics among major customers.\nBroadcom is also poised to benefit from higher demand for its data-center and server chips, aided by a rise in hybrid working models and a rapid shift to cloud by businesses during the pandemic.\nEnterprise demand rebounded sharply over 30% in the reported quarter, while revenue from semiconductor solutions is expected to grow 17% in the current quarter, Chief Executive Hock Tan said on a conference call with analysts.\nThe San Jose, California-based company forecast first-quarter revenue of about $7.60 billion, well above analysts' average estimate of $7.25 billion, according to Refinitiv data.\nFourth-quarter revenue rose 15% to $7.41 billion, narrowly beating estimates of $7.36 billion, while earnings per share of $7.81 was also better than expected.\nBroadcom has also diversified beyond its core chip business and forayed into the lucrative software arena, at a time when the world grapples with supply chain disruptions and an industry-wide chip shortage. Its infrastructure software revenue grew 8% to $1.77 billion in the fourth quarter.\nThe new share repurchase program is effective until the end of next year, the company said in a separate statement.","news_type":1,"symbols_score_info":{"AVGO":0.9}},"isVote":1,"tweetType":1,"viewCount":4158,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":876457569,"gmtCreate":1637347724231,"gmtModify":1637348952680,"author":{"id":"4095056182380350","authorId":"4095056182380350","name":"Wonderivy","avatar":"https://static.tigerbbs.com/6baa7ecbc66f9246e804ad8342fd6e05","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4095056182380350","idStr":"4095056182380350"},"themes":[],"title":"","htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/876457569","repostId":"1144455380","repostType":4,"repost":{"id":"1144455380","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637328728,"share":"https://www.laohunote.com/m/news/1144455380?lang=zh_CN&edition=full","pubTime":"2021-11-19 21:32","market":"us","language":"en","title":"Pfizer and BioNTech SE stocks climbed about 2% in premarket trading<blockquote>辉瑞和 BioNTech SE 股票在盘前交易中上涨约 2%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1144455380","media":"Tiger Newspress","summary":"Pfizer and BioNTech SE stocks climbed about 2% in premarket trading after they received expanded U.S","content":"<p>Pfizer and BioNTech SE stocks climbed about 2%&nbsp;in premarket trading&nbsp;after&nbsp;they received expanded U.S. FDA emergency use authorization of booster to include individuals 18 and older.</p><p><blockquote>辉瑞和 BioNTech SE 的股价在盘前交易中上涨约 2%，此前它们获得了美国 FDA 扩大的加强剂紧急使用授权，将 18 岁及以上的个人包括在内。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/a0ee0544027cc35ceeb2a44c7caf0848\" tg-width=\"850\" tg-height=\"619\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/026143e67c4e4f63fadd07b9b23e1301\" tg-width=\"850\" tg-height=\"617\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> Pfizer Inc.&nbsp;and BioNTech SE&nbsp;today announced that the U.S. Food and Drug Administration (FDA) has expanded the emergency use authorization (EUA) of a booster dose of the Pfizer-BioNTech COVID-19 Vaccine to include individuals 18 years of age and older. The booster dose is to be administered at least six months after completion of the primary series, and is the same dosage strength as the doses in the primary series.</p><p><blockquote>辉瑞公司和BioNTech SE今天宣布，美国。美国食品药品监督管理局（FDA）已经扩大了辉瑞-BioNTech新冠肺炎疫苗加强剂量的紧急使用授权（EUA），将18岁及以上的个人包括在内。加强剂量应在初级系列完成后至少六个月施用，剂量强度与初级系列中的剂量相同。</blockquote></p><p> “As we near the two-year mark in our fight against COVID-19, we have reached another critical milestone with the expanded authorization of a booster dose of our COVID-19 vaccine in individuals 18 years and older,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “With boosters, more adults will now have the opportunity to help preserve a high-level of protection against this disease. We are grateful to the FDA for their rigorous review, and the action taken today that we hope will help accelerate our path out of this pandemic.”</p><p><blockquote>“辉瑞公司董事长兼首席执行官阿尔伯特-布尔拉（Albert Bourla）说：”随着我们抗击 COVID-19 的两年大关接近，我们又达到了一个重要的里程碑，扩大了 18 岁及以上人群接种 COVID-19 疫苗加强剂量的授权。“有了加强剂，更多的成年人现在将有机会帮助保持对这种疾病的高水平保护。我们感谢美国食品及药物管理局的严格审查，我们希望今天采取的行动将有助于加快我们摆脱这一大流行病的步伐。”</blockquote></p><p> “Today’s FDA decision is supported by clinical data showing robust immune responses following a booster dose of our vaccine, exceeding what has been seen even after the completion of the highly-effective two-dose primary schedule,” said Ugur Sahin, M.D., CEO and Co-founder of BioNTech. “These data suggest a booster dose of our vaccine has the potential to maintain a high-level of protection against tested variants, including Delta.”</p><p><blockquote>“BioNTech公司首席执行官兼联合创始人、医学博士乌古尔-沙欣（Ugur Sahin）说：”今天美国食品和药物管理局的决定得到了临床数据的支持，这些数据显示，我们的疫苗加强剂量后会产生强劲的免疫反应，甚至超过了高效的两剂初级接种方案完成后的免疫反应。“这些数据表明，我们疫苗的加强剂量有可能对包括德尔塔在内的测试变种保持高水平的保护”。</blockquote></p><p> In October, the companies announced positive topline results from the trial showing that a booster dose administered to individuals who previously received the Pfizer-BioNTech primary two-dose series demonstrated a relative vaccine efficacy of 95% when compared to those who did not receive a booster. Thus far, these are the first and only efficacy data disclosed from any randomized, controlled COVID-19 vaccine booster trial. The adverse event profile was generally consistent with other clinical safety data for the vaccine, with no new safety concerns identified.</p><p><blockquote>10 月，两家公司宣布了该试验的积极顶线结果显示，与未接受加强剂的人相比，对先前接受辉瑞-BioNTech 初级两剂系列的个体施用的加强剂量显示出 95% 的相对疫苗效力。到目前为止，这些是任何随机对照新冠肺炎疫苗加强试验中披露的第一个也是唯一一个疗效数据。不良事件概况与疫苗的其他临床安全性数据大致一致，未发现新的安全性问题。</blockquote></p><p> A booster dose of the Pfizer-BioNTech COVID-19 Vaccine was previously authorized by the FDA for emergency use after completion of a primary series in individuals 65 years of age and older, individuals 18 through 64 years of age at high risk of severe COVID-19, and individuals 18 through 64 years of age with frequent institutional or occupational exposure to SARS-CoV-2, as well as eligible individuals who have completed primary vaccination with a different authorized COVID-19 vaccine.</p><p><blockquote>辉瑞-BioNTech新冠肺炎疫苗的加强剂量此前已被FDA授权在65岁及以上的个体、18至64岁的严重新冠肺炎高风险个体和18至64岁的个体中紧急使用。经常在机构或职业中接触新型冠状病毒的18至64岁的个体，以及已完成不同授权新冠肺炎疫苗初次接种的合格个体。</blockquote></p><p> Pfizer and BioNTech continue to supply the vaccine, including sufficient volume for boosters, under their existing supply agreement with the U.S. government, which continues through April 2022. The companies do not expect that today’s news will impact the existing supply agreements in place with governments and international health organizations around the world.</p><p><blockquote>辉瑞和 BioNTech 根据与美国政府的现有供应协议继续供应疫苗，包括足够数量的加强剂，该协议将持续到 2022 年 4 月。这些公司预计今天的消息不会影响与世界各国政府和国际卫生组织现有的供应协议。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer and BioNTech SE stocks climbed about 2% in premarket trading<blockquote>辉瑞和 BioNTech SE 股票在盘前交易中上涨约 2%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer and BioNTech SE stocks climbed about 2% in premarket trading<blockquote>辉瑞和 BioNTech SE 股票在盘前交易中上涨约 2%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-19 21:32</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Pfizer and BioNTech SE stocks climbed about 2%&nbsp;in premarket trading&nbsp;after&nbsp;they received expanded U.S. FDA emergency use authorization of booster to include individuals 18 and older.</p><p><blockquote>辉瑞和 BioNTech SE 的股价在盘前交易中上涨约 2%，此前它们获得了美国 FDA 扩大的加强剂紧急使用授权，将 18 岁及以上的个人包括在内。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/a0ee0544027cc35ceeb2a44c7caf0848\" tg-width=\"850\" tg-height=\"619\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/026143e67c4e4f63fadd07b9b23e1301\" tg-width=\"850\" tg-height=\"617\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> Pfizer Inc.&nbsp;and BioNTech SE&nbsp;today announced that the U.S. Food and Drug Administration (FDA) has expanded the emergency use authorization (EUA) of a booster dose of the Pfizer-BioNTech COVID-19 Vaccine to include individuals 18 years of age and older. The booster dose is to be administered at least six months after completion of the primary series, and is the same dosage strength as the doses in the primary series.</p><p><blockquote>辉瑞公司和BioNTech SE今天宣布，美国。美国食品药品监督管理局（FDA）已经扩大了辉瑞-BioNTech新冠肺炎疫苗加强剂量的紧急使用授权（EUA），将18岁及以上的个人包括在内。加强剂量应在初级系列完成后至少六个月施用，剂量强度与初级系列中的剂量相同。</blockquote></p><p> “As we near the two-year mark in our fight against COVID-19, we have reached another critical milestone with the expanded authorization of a booster dose of our COVID-19 vaccine in individuals 18 years and older,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “With boosters, more adults will now have the opportunity to help preserve a high-level of protection against this disease. We are grateful to the FDA for their rigorous review, and the action taken today that we hope will help accelerate our path out of this pandemic.”</p><p><blockquote>“辉瑞公司董事长兼首席执行官阿尔伯特-布尔拉（Albert Bourla）说：”随着我们抗击 COVID-19 的两年大关接近，我们又达到了一个重要的里程碑，扩大了 18 岁及以上人群接种 COVID-19 疫苗加强剂量的授权。“有了加强剂，更多的成年人现在将有机会帮助保持对这种疾病的高水平保护。我们感谢美国食品及药物管理局的严格审查，我们希望今天采取的行动将有助于加快我们摆脱这一大流行病的步伐。”</blockquote></p><p> “Today’s FDA decision is supported by clinical data showing robust immune responses following a booster dose of our vaccine, exceeding what has been seen even after the completion of the highly-effective two-dose primary schedule,” said Ugur Sahin, M.D., CEO and Co-founder of BioNTech. “These data suggest a booster dose of our vaccine has the potential to maintain a high-level of protection against tested variants, including Delta.”</p><p><blockquote>“BioNTech公司首席执行官兼联合创始人、医学博士乌古尔-沙欣（Ugur Sahin）说：”今天美国食品和药物管理局的决定得到了临床数据的支持，这些数据显示，我们的疫苗加强剂量后会产生强劲的免疫反应，甚至超过了高效的两剂初级接种方案完成后的免疫反应。“这些数据表明，我们疫苗的加强剂量有可能对包括德尔塔在内的测试变种保持高水平的保护”。</blockquote></p><p> In October, the companies announced positive topline results from the trial showing that a booster dose administered to individuals who previously received the Pfizer-BioNTech primary two-dose series demonstrated a relative vaccine efficacy of 95% when compared to those who did not receive a booster. Thus far, these are the first and only efficacy data disclosed from any randomized, controlled COVID-19 vaccine booster trial. The adverse event profile was generally consistent with other clinical safety data for the vaccine, with no new safety concerns identified.</p><p><blockquote>10 月，两家公司宣布了该试验的积极顶线结果显示，与未接受加强剂的人相比，对先前接受辉瑞-BioNTech 初级两剂系列的个体施用的加强剂量显示出 95% 的相对疫苗效力。到目前为止，这些是任何随机对照新冠肺炎疫苗加强试验中披露的第一个也是唯一一个疗效数据。不良事件概况与疫苗的其他临床安全性数据大致一致，未发现新的安全性问题。</blockquote></p><p> A booster dose of the Pfizer-BioNTech COVID-19 Vaccine was previously authorized by the FDA for emergency use after completion of a primary series in individuals 65 years of age and older, individuals 18 through 64 years of age at high risk of severe COVID-19, and individuals 18 through 64 years of age with frequent institutional or occupational exposure to SARS-CoV-2, as well as eligible individuals who have completed primary vaccination with a different authorized COVID-19 vaccine.</p><p><blockquote>辉瑞-BioNTech新冠肺炎疫苗的加强剂量此前已被FDA授权在65岁及以上的个体、18至64岁的严重新冠肺炎高风险个体和18至64岁的个体中紧急使用。经常在机构或职业中接触新型冠状病毒的18至64岁的个体，以及已完成不同授权新冠肺炎疫苗初次接种的合格个体。</blockquote></p><p> Pfizer and BioNTech continue to supply the vaccine, including sufficient volume for boosters, under their existing supply agreement with the U.S. government, which continues through April 2022. The companies do not expect that today’s news will impact the existing supply agreements in place with governments and international health organizations around the world.</p><p><blockquote>辉瑞和 BioNTech 根据与美国政府的现有供应协议继续供应疫苗，包括足够数量的加强剂，该协议将持续到 2022 年 4 月。这些公司预计今天的消息不会影响与世界各国政府和国际卫生组织现有的供应协议。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1144455380","content_text":"Pfizer and BioNTech SE stocks climbed about 2% in premarket trading after they received expanded U.S. FDA emergency use authorization of booster to include individuals 18 and older.\n\nPfizer Inc. and BioNTech SE today announced that the U.S. Food and Drug Administration (FDA) has expanded the emergency use authorization (EUA) of a booster dose of the Pfizer-BioNTech COVID-19 Vaccine to include individuals 18 years of age and older. The booster dose is to be administered at least six months after completion of the primary series, and is the same dosage strength as the doses in the primary series.\n“As we near the two-year mark in our fight against COVID-19, we have reached another critical milestone with the expanded authorization of a booster dose of our COVID-19 vaccine in individuals 18 years and older,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “With boosters, more adults will now have the opportunity to help preserve a high-level of protection against this disease. We are grateful to the FDA for their rigorous review, and the action taken today that we hope will help accelerate our path out of this pandemic.”\n“Today’s FDA decision is supported by clinical data showing robust immune responses following a booster dose of our vaccine, exceeding what has been seen even after the completion of the highly-effective two-dose primary schedule,” said Ugur Sahin, M.D., CEO and Co-founder of BioNTech. “These data suggest a booster dose of our vaccine has the potential to maintain a high-level of protection against tested variants, including Delta.”\nIn October, the companies announced positive topline results from the trial showing that a booster dose administered to individuals who previously received the Pfizer-BioNTech primary two-dose series demonstrated a relative vaccine efficacy of 95% when compared to those who did not receive a booster. Thus far, these are the first and only efficacy data disclosed from any randomized, controlled COVID-19 vaccine booster trial. The adverse event profile was generally consistent with other clinical safety data for the vaccine, with no new safety concerns identified.\nA booster dose of the Pfizer-BioNTech COVID-19 Vaccine was previously authorized by the FDA for emergency use after completion of a primary series in individuals 65 years of age and older, individuals 18 through 64 years of age at high risk of severe COVID-19, and individuals 18 through 64 years of age with frequent institutional or occupational exposure to SARS-CoV-2, as well as eligible individuals who have completed primary vaccination with a different authorized COVID-19 vaccine.\nPfizer and BioNTech continue to supply the vaccine, including sufficient volume for boosters, under their existing supply agreement with the U.S. government, which continues through April 2022. The companies do not expect that today’s news will impact the existing supply agreements in place with governments and international health organizations around the world.","news_type":1,"symbols_score_info":{"PFE":0.9,"BNTX":0.9}},"isVote":1,"tweetType":1,"viewCount":3014,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":605847523,"gmtCreate":1639148356892,"gmtModify":1639148356892,"author":{"id":"4095056182380350","authorId":"4095056182380350","name":"Wonderivy","avatar":"https://static.tigerbbs.com/6baa7ecbc66f9246e804ad8342fd6e05","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4095056182380350","idStr":"4095056182380350"},"themes":[],"title":"","htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/605847523","repostId":"1100115506","repostType":4,"repost":{"id":"1100115506","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639138188,"share":"https://www.laohunote.com/m/news/1100115506?lang=zh_CN&edition=full","pubTime":"2021-12-10 20:09","market":"us","language":"en","title":"Some vaccine stocks dropped in premarket trading<blockquote>部分疫苗股盘前交易下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1100115506","media":"Tiger Newspress","summary":"Some vaccine stocks dropped in premarket trading.Moderna fell more than 6%,BioNTech and Novavax fell","content":"<p>Some vaccine stocks dropped in premarket trading.Moderna fell more than 6%,BioNTech and Novavax fell about 2%.</p><p><blockquote>一些疫苗股在盘前交易中下跌。Moderna下跌超过6%，BioNTech和Novavax下跌约2%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/8a520d484bb38c42dea515aeca96c8b3\" tg-width=\"843\" tg-height=\"623\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/3f4e9ce656bcb771198057d217489677\" tg-width=\"843\" tg-height=\"618\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/fd626ba47bec50af63916a31695eca4c\" tg-width=\"843\" tg-height=\"621\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Some vaccine stocks dropped in premarket trading<blockquote>部分疫苗股盘前交易下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSome vaccine stocks dropped in premarket trading<blockquote>部分疫苗股盘前交易下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-10 20:09</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Some vaccine stocks dropped in premarket trading.Moderna fell more than 6%,BioNTech and Novavax fell about 2%.</p><p><blockquote>一些疫苗股在盘前交易中下跌。Moderna下跌超过6%，BioNTech和Novavax下跌约2%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/8a520d484bb38c42dea515aeca96c8b3\" tg-width=\"843\" tg-height=\"623\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/3f4e9ce656bcb771198057d217489677\" tg-width=\"843\" tg-height=\"618\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/fd626ba47bec50af63916a31695eca4c\" tg-width=\"843\" tg-height=\"621\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","MRNA":"Moderna, Inc.","BNTX":"BioNTech SE"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1100115506","content_text":"Some vaccine stocks dropped in premarket trading.Moderna fell more than 6%,BioNTech and Novavax fell about 2%.","news_type":1,"symbols_score_info":{"NVAX":0.9,"BNTX":0.9,"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":3730,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605844711,"gmtCreate":1639148305207,"gmtModify":1639148305207,"author":{"id":"4095056182380350","authorId":"4095056182380350","name":"Wonderivy","avatar":"https://static.tigerbbs.com/6baa7ecbc66f9246e804ad8342fd6e05","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4095056182380350","idStr":"4095056182380350"},"themes":[],"title":"","htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/605844711","repostId":"1191100998","repostType":4,"repost":{"id":"1191100998","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639134697,"share":"https://www.laohunote.com/m/news/1191100998?lang=zh_CN&edition=full","pubTime":"2021-12-10 19:11","market":"us","language":"en","title":"Broadcom stock jumped nearly 7% in premarket trading<blockquote>博通股价在盘前交易中上涨近 7%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1191100998","media":"Tiger Newspress","summary":"Broadcom stock jumped nearly 7% in premarket trading as the semiconductor firm saw upbeat first-quar","content":"<p>Broadcom stock jumped nearly 7% in premarket trading&nbsp;as&nbsp;the&nbsp;semiconductor firm saw upbeat first-quarter sales, unveiled $10 bln buyback plan.</p><p><blockquote>博通股价在盘前交易中上涨近 7%，这家半导体公司第一季度销售乐观，并公布了 100 亿美元的回购计划。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/f168e8acd44244ccac5c7ae151b9c6be\" tg-width=\"840\" tg-height=\"617\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> Semiconductor firm Broadcom Inc&nbsp;forecast first-quarter revenue above Wall Street expectations and announced a $10 billion share buyback plan on Thursday, banking on a rebound in enterprise spending and sustained demand from cloud computing companies.</p><p><blockquote>半导体公司博通公司预测第一季度收入高于华尔街预期，并于周四宣布了一项 100 亿美元的股票回购计划，指望企业支出反弹和云计算公司的持续需求。</blockquote></p><p> Analysts have pointed to strong near-term demand for Broadcom's radio frequency and wireless chips as telecom firms spend more to roll out 5G technology, and continued strength in its broadband division. The company counts smartphone giants Apple Inc&nbsp;and Samsung Electronics&nbsp;among major customers.</p><p><blockquote>分析师指出，随着电信公司投入更多资金推出 5G 技术，以及其宽带部门持续走强，近期对博通射频和无线芯片的需求强劲。该公司的主要客户包括智能手机巨头苹果公司和三星电子。</blockquote></p><p> Broadcom is also poised to benefit from higher demand for its data-center and server chips, aided by a rise in hybrid working models and a rapid shift to cloud by businesses during the pandemic.</p><p><blockquote>得益于混合工作模式的兴起以及大流行期间企业向云的快速转变，博通还将受益于对其数据中心和服务器芯片的更高需求。</blockquote></p><p> Enterprise demand rebounded sharply over 30% in the reported quarter, while revenue from semiconductor solutions is expected to grow 17% in the current quarter, Chief Executive Hock Tan said on a conference call with analysts.</p><p><blockquote>首席执行官 Hock Tan 在与分析师举行的电话会议上表示，报告季度企业需求大幅反弹超过 30%，而本季度半导体解决方案收入预计将增长 17%。</blockquote></p><p> The San Jose, California-based company forecast first-quarter revenue of about $7.60 billion, well above analysts' average estimate of $7.25 billion, according to Refinitiv data.</p><p><blockquote>根据 Refinitiv 的数据，这家总部位于加利福尼亚州圣何塞的公司预计第一季度收入约为 76.0 亿美元，远高于分析师平均预期的 72.5 亿美元。</blockquote></p><p> Fourth-quarter revenue rose 15% to $7.41 billion, narrowly beating estimates of $7.36 billion, while earnings per share of $7.81 was also better than expected.</p><p><blockquote>第四季度收入增长 15%，达到 74.1 亿美元，略高于预期的 73.6 亿美元，而每股收益 7.81 美元也好于预期。</blockquote></p><p> Broadcom has also diversified beyond its core chip business and forayed into the lucrative software arena, at a time when the world grapples with supply chain disruptions and an industry-wide chip shortage. Its infrastructure software revenue grew 8% to $1.77 billion in the fourth quarter.</p><p><blockquote>在全球努力应对供应链中断和全行业芯片短缺之际，博通还在核心芯片业务之外实现了多元化，进军利润丰厚的软件领域。第四季度其基础设施软件收入增长 8%，达到 17.7 亿美元。</blockquote></p><p> The new share repurchase program is effective until the end of next year, the company said in a separate statement.</p><p><blockquote>该公司在另一份声明中表示，新的股票回购计划有效期至明年年底。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Broadcom stock jumped nearly 7% in premarket trading<blockquote>博通股价在盘前交易中上涨近 7%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBroadcom stock jumped nearly 7% in premarket trading<blockquote>博通股价在盘前交易中上涨近 7%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-10 19:11</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Broadcom stock jumped nearly 7% in premarket trading&nbsp;as&nbsp;the&nbsp;semiconductor firm saw upbeat first-quarter sales, unveiled $10 bln buyback plan.</p><p><blockquote>博通股价在盘前交易中上涨近 7%，这家半导体公司第一季度销售乐观，并公布了 100 亿美元的回购计划。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/f168e8acd44244ccac5c7ae151b9c6be\" tg-width=\"840\" tg-height=\"617\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> Semiconductor firm Broadcom Inc&nbsp;forecast first-quarter revenue above Wall Street expectations and announced a $10 billion share buyback plan on Thursday, banking on a rebound in enterprise spending and sustained demand from cloud computing companies.</p><p><blockquote>半导体公司博通公司预测第一季度收入高于华尔街预期，并于周四宣布了一项 100 亿美元的股票回购计划，指望企业支出反弹和云计算公司的持续需求。</blockquote></p><p> Analysts have pointed to strong near-term demand for Broadcom's radio frequency and wireless chips as telecom firms spend more to roll out 5G technology, and continued strength in its broadband division. The company counts smartphone giants Apple Inc&nbsp;and Samsung Electronics&nbsp;among major customers.</p><p><blockquote>分析师指出，随着电信公司投入更多资金推出 5G 技术，以及其宽带部门持续走强，近期对博通射频和无线芯片的需求强劲。该公司的主要客户包括智能手机巨头苹果公司和三星电子。</blockquote></p><p> Broadcom is also poised to benefit from higher demand for its data-center and server chips, aided by a rise in hybrid working models and a rapid shift to cloud by businesses during the pandemic.</p><p><blockquote>得益于混合工作模式的兴起以及大流行期间企业向云的快速转变，博通还将受益于对其数据中心和服务器芯片的更高需求。</blockquote></p><p> Enterprise demand rebounded sharply over 30% in the reported quarter, while revenue from semiconductor solutions is expected to grow 17% in the current quarter, Chief Executive Hock Tan said on a conference call with analysts.</p><p><blockquote>首席执行官 Hock Tan 在与分析师举行的电话会议上表示，报告季度企业需求大幅反弹超过 30%，而本季度半导体解决方案收入预计将增长 17%。</blockquote></p><p> The San Jose, California-based company forecast first-quarter revenue of about $7.60 billion, well above analysts' average estimate of $7.25 billion, according to Refinitiv data.</p><p><blockquote>根据 Refinitiv 的数据，这家总部位于加利福尼亚州圣何塞的公司预计第一季度收入约为 76.0 亿美元，远高于分析师平均预期的 72.5 亿美元。</blockquote></p><p> Fourth-quarter revenue rose 15% to $7.41 billion, narrowly beating estimates of $7.36 billion, while earnings per share of $7.81 was also better than expected.</p><p><blockquote>第四季度收入增长 15%，达到 74.1 亿美元，略高于预期的 73.6 亿美元，而每股收益 7.81 美元也好于预期。</blockquote></p><p> Broadcom has also diversified beyond its core chip business and forayed into the lucrative software arena, at a time when the world grapples with supply chain disruptions and an industry-wide chip shortage. Its infrastructure software revenue grew 8% to $1.77 billion in the fourth quarter.</p><p><blockquote>在全球努力应对供应链中断和全行业芯片短缺之际，博通还在核心芯片业务之外实现了多元化，进军利润丰厚的软件领域。第四季度其基础设施软件收入增长 8%，达到 17.7 亿美元。</blockquote></p><p> The new share repurchase program is effective until the end of next year, the company said in a separate statement.</p><p><blockquote>该公司在另一份声明中表示，新的股票回购计划有效期至明年年底。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AVGO":"博通"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191100998","content_text":"Broadcom stock jumped nearly 7% in premarket trading as the semiconductor firm saw upbeat first-quarter sales, unveiled $10 bln buyback plan.\n\nSemiconductor firm Broadcom Inc forecast first-quarter revenue above Wall Street expectations and announced a $10 billion share buyback plan on Thursday, banking on a rebound in enterprise spending and sustained demand from cloud computing companies.\nAnalysts have pointed to strong near-term demand for Broadcom's radio frequency and wireless chips as telecom firms spend more to roll out 5G technology, and continued strength in its broadband division. The company counts smartphone giants Apple Inc and Samsung Electronics among major customers.\nBroadcom is also poised to benefit from higher demand for its data-center and server chips, aided by a rise in hybrid working models and a rapid shift to cloud by businesses during the pandemic.\nEnterprise demand rebounded sharply over 30% in the reported quarter, while revenue from semiconductor solutions is expected to grow 17% in the current quarter, Chief Executive Hock Tan said on a conference call with analysts.\nThe San Jose, California-based company forecast first-quarter revenue of about $7.60 billion, well above analysts' average estimate of $7.25 billion, according to Refinitiv data.\nFourth-quarter revenue rose 15% to $7.41 billion, narrowly beating estimates of $7.36 billion, while earnings per share of $7.81 was also better than expected.\nBroadcom has also diversified beyond its core chip business and forayed into the lucrative software arena, at a time when the world grapples with supply chain disruptions and an industry-wide chip shortage. Its infrastructure software revenue grew 8% to $1.77 billion in the fourth quarter.\nThe new share repurchase program is effective until the end of next year, the company said in a separate statement.","news_type":1,"symbols_score_info":{"AVGO":0.9}},"isVote":1,"tweetType":1,"viewCount":4158,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":876457569,"gmtCreate":1637347724231,"gmtModify":1637348952680,"author":{"id":"4095056182380350","authorId":"4095056182380350","name":"Wonderivy","avatar":"https://static.tigerbbs.com/6baa7ecbc66f9246e804ad8342fd6e05","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4095056182380350","idStr":"4095056182380350"},"themes":[],"title":"","htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/876457569","repostId":"1144455380","repostType":4,"repost":{"id":"1144455380","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637328728,"share":"https://www.laohunote.com/m/news/1144455380?lang=zh_CN&edition=full","pubTime":"2021-11-19 21:32","market":"us","language":"en","title":"Pfizer and BioNTech SE stocks climbed about 2% in premarket trading<blockquote>辉瑞和 BioNTech SE 股票在盘前交易中上涨约 2%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1144455380","media":"Tiger Newspress","summary":"Pfizer and BioNTech SE stocks climbed about 2% in premarket trading after they received expanded U.S","content":"<p>Pfizer and BioNTech SE stocks climbed about 2%&nbsp;in premarket trading&nbsp;after&nbsp;they received expanded U.S. FDA emergency use authorization of booster to include individuals 18 and older.</p><p><blockquote>辉瑞和 BioNTech SE 的股价在盘前交易中上涨约 2%，此前它们获得了美国 FDA 扩大的加强剂紧急使用授权，将 18 岁及以上的个人包括在内。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/a0ee0544027cc35ceeb2a44c7caf0848\" tg-width=\"850\" tg-height=\"619\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/026143e67c4e4f63fadd07b9b23e1301\" tg-width=\"850\" tg-height=\"617\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> Pfizer Inc.&nbsp;and BioNTech SE&nbsp;today announced that the U.S. Food and Drug Administration (FDA) has expanded the emergency use authorization (EUA) of a booster dose of the Pfizer-BioNTech COVID-19 Vaccine to include individuals 18 years of age and older. The booster dose is to be administered at least six months after completion of the primary series, and is the same dosage strength as the doses in the primary series.</p><p><blockquote>辉瑞公司和BioNTech SE今天宣布，美国。美国食品药品监督管理局（FDA）已经扩大了辉瑞-BioNTech新冠肺炎疫苗加强剂量的紧急使用授权（EUA），将18岁及以上的个人包括在内。加强剂量应在初级系列完成后至少六个月施用，剂量强度与初级系列中的剂量相同。</blockquote></p><p> “As we near the two-year mark in our fight against COVID-19, we have reached another critical milestone with the expanded authorization of a booster dose of our COVID-19 vaccine in individuals 18 years and older,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “With boosters, more adults will now have the opportunity to help preserve a high-level of protection against this disease. We are grateful to the FDA for their rigorous review, and the action taken today that we hope will help accelerate our path out of this pandemic.”</p><p><blockquote>“辉瑞公司董事长兼首席执行官阿尔伯特-布尔拉（Albert Bourla）说：”随着我们抗击 COVID-19 的两年大关接近，我们又达到了一个重要的里程碑，扩大了 18 岁及以上人群接种 COVID-19 疫苗加强剂量的授权。“有了加强剂，更多的成年人现在将有机会帮助保持对这种疾病的高水平保护。我们感谢美国食品及药物管理局的严格审查，我们希望今天采取的行动将有助于加快我们摆脱这一大流行病的步伐。”</blockquote></p><p> “Today’s FDA decision is supported by clinical data showing robust immune responses following a booster dose of our vaccine, exceeding what has been seen even after the completion of the highly-effective two-dose primary schedule,” said Ugur Sahin, M.D., CEO and Co-founder of BioNTech. “These data suggest a booster dose of our vaccine has the potential to maintain a high-level of protection against tested variants, including Delta.”</p><p><blockquote>“BioNTech公司首席执行官兼联合创始人、医学博士乌古尔-沙欣（Ugur Sahin）说：”今天美国食品和药物管理局的决定得到了临床数据的支持，这些数据显示，我们的疫苗加强剂量后会产生强劲的免疫反应，甚至超过了高效的两剂初级接种方案完成后的免疫反应。“这些数据表明，我们疫苗的加强剂量有可能对包括德尔塔在内的测试变种保持高水平的保护”。</blockquote></p><p> In October, the companies announced positive topline results from the trial showing that a booster dose administered to individuals who previously received the Pfizer-BioNTech primary two-dose series demonstrated a relative vaccine efficacy of 95% when compared to those who did not receive a booster. Thus far, these are the first and only efficacy data disclosed from any randomized, controlled COVID-19 vaccine booster trial. The adverse event profile was generally consistent with other clinical safety data for the vaccine, with no new safety concerns identified.</p><p><blockquote>10 月，两家公司宣布了该试验的积极顶线结果显示，与未接受加强剂的人相比，对先前接受辉瑞-BioNTech 初级两剂系列的个体施用的加强剂量显示出 95% 的相对疫苗效力。到目前为止，这些是任何随机对照新冠肺炎疫苗加强试验中披露的第一个也是唯一一个疗效数据。不良事件概况与疫苗的其他临床安全性数据大致一致，未发现新的安全性问题。</blockquote></p><p> A booster dose of the Pfizer-BioNTech COVID-19 Vaccine was previously authorized by the FDA for emergency use after completion of a primary series in individuals 65 years of age and older, individuals 18 through 64 years of age at high risk of severe COVID-19, and individuals 18 through 64 years of age with frequent institutional or occupational exposure to SARS-CoV-2, as well as eligible individuals who have completed primary vaccination with a different authorized COVID-19 vaccine.</p><p><blockquote>辉瑞-BioNTech新冠肺炎疫苗的加强剂量此前已被FDA授权在65岁及以上的个体、18至64岁的严重新冠肺炎高风险个体和18至64岁的个体中紧急使用。经常在机构或职业中接触新型冠状病毒的18至64岁的个体，以及已完成不同授权新冠肺炎疫苗初次接种的合格个体。</blockquote></p><p> Pfizer and BioNTech continue to supply the vaccine, including sufficient volume for boosters, under their existing supply agreement with the U.S. government, which continues through April 2022. The companies do not expect that today’s news will impact the existing supply agreements in place with governments and international health organizations around the world.</p><p><blockquote>辉瑞和 BioNTech 根据与美国政府的现有供应协议继续供应疫苗，包括足够数量的加强剂，该协议将持续到 2022 年 4 月。这些公司预计今天的消息不会影响与世界各国政府和国际卫生组织现有的供应协议。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer and BioNTech SE stocks climbed about 2% in premarket trading<blockquote>辉瑞和 BioNTech SE 股票在盘前交易中上涨约 2%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer and BioNTech SE stocks climbed about 2% in premarket trading<blockquote>辉瑞和 BioNTech SE 股票在盘前交易中上涨约 2%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-19 21:32</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Pfizer and BioNTech SE stocks climbed about 2%&nbsp;in premarket trading&nbsp;after&nbsp;they received expanded U.S. FDA emergency use authorization of booster to include individuals 18 and older.</p><p><blockquote>辉瑞和 BioNTech SE 的股价在盘前交易中上涨约 2%，此前它们获得了美国 FDA 扩大的加强剂紧急使用授权，将 18 岁及以上的个人包括在内。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/a0ee0544027cc35ceeb2a44c7caf0848\" tg-width=\"850\" tg-height=\"619\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/026143e67c4e4f63fadd07b9b23e1301\" tg-width=\"850\" tg-height=\"617\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> Pfizer Inc.&nbsp;and BioNTech SE&nbsp;today announced that the U.S. Food and Drug Administration (FDA) has expanded the emergency use authorization (EUA) of a booster dose of the Pfizer-BioNTech COVID-19 Vaccine to include individuals 18 years of age and older. The booster dose is to be administered at least six months after completion of the primary series, and is the same dosage strength as the doses in the primary series.</p><p><blockquote>辉瑞公司和BioNTech SE今天宣布，美国。美国食品药品监督管理局（FDA）已经扩大了辉瑞-BioNTech新冠肺炎疫苗加强剂量的紧急使用授权（EUA），将18岁及以上的个人包括在内。加强剂量应在初级系列完成后至少六个月施用，剂量强度与初级系列中的剂量相同。</blockquote></p><p> “As we near the two-year mark in our fight against COVID-19, we have reached another critical milestone with the expanded authorization of a booster dose of our COVID-19 vaccine in individuals 18 years and older,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “With boosters, more adults will now have the opportunity to help preserve a high-level of protection against this disease. We are grateful to the FDA for their rigorous review, and the action taken today that we hope will help accelerate our path out of this pandemic.”</p><p><blockquote>“辉瑞公司董事长兼首席执行官阿尔伯特-布尔拉（Albert Bourla）说：”随着我们抗击 COVID-19 的两年大关接近，我们又达到了一个重要的里程碑，扩大了 18 岁及以上人群接种 COVID-19 疫苗加强剂量的授权。“有了加强剂，更多的成年人现在将有机会帮助保持对这种疾病的高水平保护。我们感谢美国食品及药物管理局的严格审查，我们希望今天采取的行动将有助于加快我们摆脱这一大流行病的步伐。”</blockquote></p><p> “Today’s FDA decision is supported by clinical data showing robust immune responses following a booster dose of our vaccine, exceeding what has been seen even after the completion of the highly-effective two-dose primary schedule,” said Ugur Sahin, M.D., CEO and Co-founder of BioNTech. “These data suggest a booster dose of our vaccine has the potential to maintain a high-level of protection against tested variants, including Delta.”</p><p><blockquote>“BioNTech公司首席执行官兼联合创始人、医学博士乌古尔-沙欣（Ugur Sahin）说：”今天美国食品和药物管理局的决定得到了临床数据的支持，这些数据显示，我们的疫苗加强剂量后会产生强劲的免疫反应，甚至超过了高效的两剂初级接种方案完成后的免疫反应。“这些数据表明，我们疫苗的加强剂量有可能对包括德尔塔在内的测试变种保持高水平的保护”。</blockquote></p><p> In October, the companies announced positive topline results from the trial showing that a booster dose administered to individuals who previously received the Pfizer-BioNTech primary two-dose series demonstrated a relative vaccine efficacy of 95% when compared to those who did not receive a booster. Thus far, these are the first and only efficacy data disclosed from any randomized, controlled COVID-19 vaccine booster trial. The adverse event profile was generally consistent with other clinical safety data for the vaccine, with no new safety concerns identified.</p><p><blockquote>10 月，两家公司宣布了该试验的积极顶线结果显示，与未接受加强剂的人相比，对先前接受辉瑞-BioNTech 初级两剂系列的个体施用的加强剂量显示出 95% 的相对疫苗效力。到目前为止，这些是任何随机对照新冠肺炎疫苗加强试验中披露的第一个也是唯一一个疗效数据。不良事件概况与疫苗的其他临床安全性数据大致一致，未发现新的安全性问题。</blockquote></p><p> A booster dose of the Pfizer-BioNTech COVID-19 Vaccine was previously authorized by the FDA for emergency use after completion of a primary series in individuals 65 years of age and older, individuals 18 through 64 years of age at high risk of severe COVID-19, and individuals 18 through 64 years of age with frequent institutional or occupational exposure to SARS-CoV-2, as well as eligible individuals who have completed primary vaccination with a different authorized COVID-19 vaccine.</p><p><blockquote>辉瑞-BioNTech新冠肺炎疫苗的加强剂量此前已被FDA授权在65岁及以上的个体、18至64岁的严重新冠肺炎高风险个体和18至64岁的个体中紧急使用。经常在机构或职业中接触新型冠状病毒的18至64岁的个体，以及已完成不同授权新冠肺炎疫苗初次接种的合格个体。</blockquote></p><p> Pfizer and BioNTech continue to supply the vaccine, including sufficient volume for boosters, under their existing supply agreement with the U.S. government, which continues through April 2022. The companies do not expect that today’s news will impact the existing supply agreements in place with governments and international health organizations around the world.</p><p><blockquote>辉瑞和 BioNTech 根据与美国政府的现有供应协议继续供应疫苗，包括足够数量的加强剂，该协议将持续到 2022 年 4 月。这些公司预计今天的消息不会影响与世界各国政府和国际卫生组织现有的供应协议。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1144455380","content_text":"Pfizer and BioNTech SE stocks climbed about 2% in premarket trading after they received expanded U.S. FDA emergency use authorization of booster to include individuals 18 and older.\n\nPfizer Inc. and BioNTech SE today announced that the U.S. Food and Drug Administration (FDA) has expanded the emergency use authorization (EUA) of a booster dose of the Pfizer-BioNTech COVID-19 Vaccine to include individuals 18 years of age and older. The booster dose is to be administered at least six months after completion of the primary series, and is the same dosage strength as the doses in the primary series.\n“As we near the two-year mark in our fight against COVID-19, we have reached another critical milestone with the expanded authorization of a booster dose of our COVID-19 vaccine in individuals 18 years and older,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “With boosters, more adults will now have the opportunity to help preserve a high-level of protection against this disease. We are grateful to the FDA for their rigorous review, and the action taken today that we hope will help accelerate our path out of this pandemic.”\n“Today’s FDA decision is supported by clinical data showing robust immune responses following a booster dose of our vaccine, exceeding what has been seen even after the completion of the highly-effective two-dose primary schedule,” said Ugur Sahin, M.D., CEO and Co-founder of BioNTech. “These data suggest a booster dose of our vaccine has the potential to maintain a high-level of protection against tested variants, including Delta.”\nIn October, the companies announced positive topline results from the trial showing that a booster dose administered to individuals who previously received the Pfizer-BioNTech primary two-dose series demonstrated a relative vaccine efficacy of 95% when compared to those who did not receive a booster. Thus far, these are the first and only efficacy data disclosed from any randomized, controlled COVID-19 vaccine booster trial. The adverse event profile was generally consistent with other clinical safety data for the vaccine, with no new safety concerns identified.\nA booster dose of the Pfizer-BioNTech COVID-19 Vaccine was previously authorized by the FDA for emergency use after completion of a primary series in individuals 65 years of age and older, individuals 18 through 64 years of age at high risk of severe COVID-19, and individuals 18 through 64 years of age with frequent institutional or occupational exposure to SARS-CoV-2, as well as eligible individuals who have completed primary vaccination with a different authorized COVID-19 vaccine.\nPfizer and BioNTech continue to supply the vaccine, including sufficient volume for boosters, under their existing supply agreement with the U.S. government, which continues through April 2022. The companies do not expect that today’s news will impact the existing supply agreements in place with governments and international health organizations around the world.","news_type":1,"symbols_score_info":{"PFE":0.9,"BNTX":0.9}},"isVote":1,"tweetType":1,"viewCount":3014,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}